Advertisement

Index by author

March 01, 1990; Volume 18,Issue 2

A

  1. Abernethy, D R

    1. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.
      S C Tsao, T H Dickinson and D R Abernethy
      Drug Metabolism and Disposition March 1990, 18 (2) 180-182;

  2. Adachi, H

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  3. Arai, M

    1. Enzymatic reduction of an epoxysuccinic acid derivative by rat cecal microflora.
      K Fukushima, M Arai, T Suwa and T Satoh
      Drug Metabolism and Disposition March 1990, 18 (2) 264-266;

  4. Arison, B

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

B

  1. Balfour, C

    1. Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form(s) of rat liver cytochrome P-450.
      J Halpert, J Y Jaw, C Balfour and L S Kaminsky
      Drug Metabolism and Disposition March 1990, 18 (2) 168-174;

  2. Bar-On, H

    1. The disposition of valpromide in rats and the isolated perfused rat liver.
      H Billig, E Ziv, H Bar-On and M Bialer
      Drug Metabolism and Disposition March 1990, 18 (2) 238-244;

  3. Beattie, I

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

  4. Bialer, M

    1. The disposition of valpromide in rats and the isolated perfused rat liver.
      H Billig, E Ziv, H Bar-On and M Bialer
      Drug Metabolism and Disposition March 1990, 18 (2) 238-244;

  5. Billig, H

    1. The disposition of valpromide in rats and the isolated perfused rat liver.
      H Billig, E Ziv, H Bar-On and M Bialer
      Drug Metabolism and Disposition March 1990, 18 (2) 238-244;

  6. Blake, T J

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

  7. Brouwer, K L

    1. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose.
      G M Pollack, K L Brouwer, K B Demby and J A Jones
      Drug Metabolism and Disposition March 1990, 18 (2) 197-202;

  8. Brunner, L J

    1. Bioavailability assessment of cyclosporine in the rat. Influence of route of administration.
      D R Luke, L J Brunner and K Vadiei
      Drug Metabolism and Disposition March 1990, 18 (2) 158-162;

  9. Buckpitt, A

    1. In vivo metabolism of isomeric naphthalene oxide glutathione conjugates.
      M Buonarati, A D Jones and A Buckpitt
      Drug Metabolism and Disposition March 1990, 18 (2) 183-189;

  10. Buonarati, M

    1. In vivo metabolism of isomeric naphthalene oxide glutathione conjugates.
      M Buonarati, A D Jones and A Buckpitt
      Drug Metabolism and Disposition March 1990, 18 (2) 183-189;

C

  1. Capello, S

    1. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam.
      S Capello, L Henderson, F DeGrazia, D Liberato, W Garland and C Town
      Drug Metabolism and Disposition March 1990, 18 (2) 190-196;

  2. Chen, I W

    1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
      S Vickers, C A Duncan, I W Chen, A Rosegay and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 138-145;

  3. Chenery, R J

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

  4. Copeland, K

    1. Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.
      K Copeland, M Lukowski, R Yatscoff, J Thliveris and N Honcharik
      Drug Metabolism and Disposition March 1990, 18 (2) 226-230;

  5. Cox, P J

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

D

  1. Daugaard, H

    1. Clearance of prednisone in isolated perfused livers of normal and uremic rats. Effects of acute and chronic cyclosporin A administration.
      M Egfjord, H Daugaard and K Olgaard
      Drug Metabolism and Disposition March 1990, 18 (2) 231-237;

  2. DeGrazia, F

    1. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam.
      S Capello, L Henderson, F DeGrazia, D Liberato, W Garland and C Town
      Drug Metabolism and Disposition March 1990, 18 (2) 190-196;

  3. Demby, K B

    1. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose.
      G M Pollack, K L Brouwer, K B Demby and J A Jones
      Drug Metabolism and Disposition March 1990, 18 (2) 197-202;

  4. Dickinson, T H

    1. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.
      S C Tsao, T H Dickinson and D R Abernethy
      Drug Metabolism and Disposition March 1990, 18 (2) 180-182;

  5. Duggan, D E

    1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
      S Vickers, C A Duncan, I W Chen, A Rosegay and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 138-145;
    2. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
      K P Vyas, P H Kari, S R Prakash and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 218-222;

  6. Duncan, C A

    1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
      S Vickers, C A Duncan, I W Chen, A Rosegay and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 138-145;

E

  1. Egfjord, M

    1. Clearance of prednisone in isolated perfused livers of normal and uremic rats. Effects of acute and chronic cyclosporin A administration.
      M Egfjord, H Daugaard and K Olgaard
      Drug Metabolism and Disposition March 1990, 18 (2) 231-237;

  2. Endo, H

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

F

  1. Filla, M S

    1. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
      T A Hultin, M S Filla and D L McCormick
      Drug Metabolism and Disposition March 1990, 18 (2) 175-179;

  2. Flesher, J W

    1. Bioalkylation of benz[a]anthracene as a biochemical probe for carcinogenic activity. Lack of bioalkylation in a series of six noncarcinogenic polynuclear aromatic hydrocarbons.
      J W Flesher and S R Myers
      Drug Metabolism and Disposition March 1990, 18 (2) 163-167;

  3. Fujihara, M

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

  4. Fukushima, K

    1. Enzymatic reduction of an epoxysuccinic acid derivative by rat cecal microflora.
      K Fukushima, M Arai, T Suwa and T Satoh
      Drug Metabolism and Disposition March 1990, 18 (2) 264-266;

G

  1. Garland, W

    1. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam.
      S Capello, L Henderson, F DeGrazia, D Liberato, W Garland and C Town
      Drug Metabolism and Disposition March 1990, 18 (2) 190-196;

H

  1. Halpert, J

    1. Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form(s) of rat liver cytochrome P-450.
      J Halpert, J Y Jaw, C Balfour and L S Kaminsky
      Drug Metabolism and Disposition March 1990, 18 (2) 168-174;

  2. Halpin, R A

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  3. Henderson, L

    1. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam.
      S Capello, L Henderson, F DeGrazia, D Liberato, W Garland and C Town
      Drug Metabolism and Disposition March 1990, 18 (2) 190-196;

  4. Hoffman, W F

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  5. Honcharik, N

    1. Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.
      K Copeland, M Lukowski, R Yatscoff, J Thliveris and N Honcharik
      Drug Metabolism and Disposition March 1990, 18 (2) 226-230;

  6. Hultin, T A

    1. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
      T A Hultin, M S Filla and D L McCormick
      Drug Metabolism and Disposition March 1990, 18 (2) 175-179;

I

  1. Ichimura, F

    1. Effect of fat tissue volume on the distribution kinetics of biperiden as a function of age in rats.
      K Yokogawa, E Nakashima and F Ichimura
      Drug Metabolism and Disposition March 1990, 18 (2) 258-263;

  2. Ishiguro, M

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  3. Ishikawa, H

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

J

  1. Jaw, J Y

    1. Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form(s) of rat liver cytochrome P-450.
      J Halpert, J Y Jaw, C Balfour and L S Kaminsky
      Drug Metabolism and Disposition March 1990, 18 (2) 168-174;

  2. Jones, A D

    1. In vivo metabolism of isomeric naphthalene oxide glutathione conjugates.
      M Buonarati, A D Jones and A Buckpitt
      Drug Metabolism and Disposition March 1990, 18 (2) 183-189;

  3. Jones, J A

    1. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose.
      G M Pollack, K L Brouwer, K B Demby and J A Jones
      Drug Metabolism and Disposition March 1990, 18 (2) 197-202;

  4. Juedes, M J

    1. Role of P-450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrene-treated rats.
      M J Juedes and D Kupfer
      Drug Metabolism and Disposition March 1990, 18 (2) 131-137;

K

  1. Kagoshima, T

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

  2. Kaminsky, L S

    1. Selective inactivation by chlorofluoroacetamides of the major phenobarbital-inducible form(s) of rat liver cytochrome P-450.
      J Halpert, J Y Jaw, C Balfour and L S Kaminsky
      Drug Metabolism and Disposition March 1990, 18 (2) 168-174;

  3. Kari, P H

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;
    2. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
      K P Vyas, P H Kari, S R Prakash and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 218-222;

  4. Klunk, L J

    1. Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine.
      J W Russell, V J Whiterock, D Marrero and L J Klunk
      Drug Metabolism and Disposition March 1990, 18 (2) 153-157;

  5. Komatsu, K

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

  6. Kravchenko, L V

    1. The effect of aspartame on the activity of rat liver xenobiotic-metabolizing enzymes.
      V A Tutelyan, L V Kravchenko and E E Kuzmina
      Drug Metabolism and Disposition March 1990, 18 (2) 223-225;

  7. Kupfer, D

    1. Role of P-450c in the formation of a reactive intermediate of chlorotrianisene (TACE) by hepatic microsomes from methylcholanthrene-treated rats.
      M J Juedes and D Kupfer
      Drug Metabolism and Disposition March 1990, 18 (2) 131-137;

  8. Kuzmina, E E

    1. The effect of aspartame on the activity of rat liver xenobiotic-metabolizing enzymes.
      V A Tutelyan, L V Kravchenko and E E Kuzmina
      Drug Metabolism and Disposition March 1990, 18 (2) 223-225;

L

  1. Liberato, D

    1. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam.
      S Capello, L Henderson, F DeGrazia, D Liberato, W Garland and C Town
      Drug Metabolism and Disposition March 1990, 18 (2) 190-196;

  2. Luke, D R

    1. Bioavailability assessment of cyclosporine in the rat. Influence of route of administration.
      D R Luke, L J Brunner and K Vadiei
      Drug Metabolism and Disposition March 1990, 18 (2) 158-162;

  3. Lukowski, M

    1. Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.
      K Copeland, M Lukowski, R Yatscoff, J Thliveris and N Honcharik
      Drug Metabolism and Disposition March 1990, 18 (2) 226-230;

M

  1. Marrero, D

    1. Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine.
      J W Russell, V J Whiterock, D Marrero and L J Klunk
      Drug Metabolism and Disposition March 1990, 18 (2) 153-157;

  2. McCormick, D L

    1. Distribution and metabolism of the retinoid, N-(4-methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-hydroxyphenyl)-all-trans-retinamide, in female mice.
      T A Hultin, M S Filla and D L McCormick
      Drug Metabolism and Disposition March 1990, 18 (2) 175-179;

  3. Migdalof, B H

    1. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
      R A Morrison, S M Singhvi, A E Peterson, D A Pocetti and B H Migdalof
      Drug Metabolism and Disposition March 1990, 18 (2) 253-257;

  4. Morrison, R A

    1. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
      R A Morrison, S M Singhvi, A E Peterson, D A Pocetti and B H Migdalof
      Drug Metabolism and Disposition March 1990, 18 (2) 253-257;

  5. Murphy, J S

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  6. Myers, S R

    1. Bioalkylation of benz[a]anthracene as a biochemical probe for carcinogenic activity. Lack of bioalkylation in a series of six noncarcinogenic polynuclear aromatic hydrocarbons.
      J W Flesher and S R Myers
      Drug Metabolism and Disposition March 1990, 18 (2) 163-167;

N

  1. Nakashima, E

    1. Effect of fat tissue volume on the distribution kinetics of biperiden as a function of age in rats.
      K Yokogawa, E Nakashima and F Ichimura
      Drug Metabolism and Disposition March 1990, 18 (2) 258-263;

  2. Nishihara, T

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  3. Noguchi, T

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  4. Norman, S J

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

O

  1. Ohnuma, N

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  2. Oldham, H G

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

  3. Olgaard, K

    1. Clearance of prednisone in isolated perfused livers of normal and uremic rats. Effects of acute and chronic cyclosporin A administration.
      M Egfjord, H Daugaard and K Olgaard
      Drug Metabolism and Disposition March 1990, 18 (2) 231-237;

P

  1. Peterson, A E

    1. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
      R A Morrison, S M Singhvi, A E Peterson, D A Pocetti and B H Migdalof
      Drug Metabolism and Disposition March 1990, 18 (2) 253-257;

  2. Pitzenberger, S M

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  3. Pocetti, D A

    1. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
      R A Morrison, S M Singhvi, A E Peterson, D A Pocetti and B H Migdalof
      Drug Metabolism and Disposition March 1990, 18 (2) 253-257;

  4. Pollack, G M

    1. Determination of hepatic blood flow in the rat using sequential infusions of indocyanine green or galactose.
      G M Pollack, K L Brouwer, K B Demby and J A Jones
      Drug Metabolism and Disposition March 1990, 18 (2) 197-202;

  5. Prakash, S R

    1. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
      K P Vyas, P H Kari, S R Prakash and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 218-222;

R

  1. Ramjit, H G

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  2. Rosegay, A

    1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
      S Vickers, C A Duncan, I W Chen, A Rosegay and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 138-145;

  3. Russell, J W

    1. Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine.
      J W Russell, V J Whiterock, D Marrero and L J Klunk
      Drug Metabolism and Disposition March 1990, 18 (2) 153-157;

S

  1. Sato, H

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  2. Satoh, T

    1. Enzymatic reduction of an epoxysuccinic acid derivative by rat cecal microflora.
      K Fukushima, M Arai, T Suwa and T Satoh
      Drug Metabolism and Disposition March 1990, 18 (2) 264-266;

  3. Schwartz, M S

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  4. Singhvi, S M

    1. Relative contribution of the gut, liver, and lung to the first-pass hydrolysis (bioactivation) of orally administered 14C-fosinopril sodium in dogs. In vivo and in vitro studies.
      R A Morrison, S M Singhvi, A E Peterson, D A Pocetti and B H Migdalof
      Drug Metabolism and Disposition March 1990, 18 (2) 253-257;

  5. Standring, P

    1. Metabolism of temelastine (SK&F 93944) in hepatocytes from rat, dog, cynomolgus monkey and man.
      H G Oldham, P Standring, S J Norman, T J Blake, I Beattie, P J Cox and R J Chenery
      Drug Metabolism and Disposition March 1990, 18 (2) 146-152;

  6. Suwa, T

    1. Enzymatic reduction of an epoxysuccinic acid derivative by rat cecal microflora.
      K Fukushima, M Arai, T Suwa and T Satoh
      Drug Metabolism and Disposition March 1990, 18 (2) 264-266;

T

  1. Takaiti, O

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

  2. Tamai, I

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  3. Thliveris, J

    1. Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.
      K Copeland, M Lukowski, R Yatscoff, J Thliveris and N Honcharik
      Drug Metabolism and Disposition March 1990, 18 (2) 226-230;

  4. Town, C

    1. The effect of the cytochrome P-450 suicide inactivator, 1-aminobenzotriazole, on the in vivo metabolism and pharmacologic activity of flurazepam.
      S Capello, L Henderson, F DeGrazia, D Liberato, W Garland and C Town
      Drug Metabolism and Disposition March 1990, 18 (2) 190-196;

  5. Tsao, S C

    1. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.
      S C Tsao, T H Dickinson and D R Abernethy
      Drug Metabolism and Disposition March 1990, 18 (2) 180-182;

  6. Tsuji, A

    1. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy.
      A Tsuji, H Sato, I Tamai, H Adachi, T Nishihara, M Ishiguro, N Ohnuma and T Noguchi
      Drug Metabolism and Disposition March 1990, 18 (2) 245-252;

  7. Tutelyan, V A

    1. The effect of aspartame on the activity of rat liver xenobiotic-metabolizing enzymes.
      V A Tutelyan, L V Kravchenko and E E Kuzmina
      Drug Metabolism and Disposition March 1990, 18 (2) 223-225;

U

  1. Ulm, E H

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;

  2. Umehara, M

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

V

  1. Vadiei, K

    1. Bioavailability assessment of cyclosporine in the rat. Influence of route of administration.
      D R Luke, L J Brunner and K Vadiei
      Drug Metabolism and Disposition March 1990, 18 (2) 158-162;

  2. Vickers, S

    1. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
      S Vickers, C A Duncan, I W Chen, A Rosegay and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 138-145;

  3. Vyas, K P

    1. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
      K P Vyas, P H Kari, S M Pitzenberger, R A Halpin, H G Ramjit, B Arison, J S Murphy, W F Hoffman, M S Schwartz and E H Ulm
      Drug Metabolism and Disposition March 1990, 18 (2) 203-211;
    2. Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.
      K P Vyas, P H Kari, S R Prakash and D E Duggan
      Drug Metabolism and Disposition March 1990, 18 (2) 218-222;

W

  1. Whiterock, V J

    1. Disposition in animals of a new anti-HIV agent: 2',3'-didehydro-3'-deoxythymidine.
      J W Russell, V J Whiterock, D Marrero and L J Klunk
      Drug Metabolism and Disposition March 1990, 18 (2) 153-157;

Y

  1. Yatscoff, R

    1. Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.
      K Copeland, M Lukowski, R Yatscoff, J Thliveris and N Honcharik
      Drug Metabolism and Disposition March 1990, 18 (2) 226-230;

  2. Yokogawa, K

    1. Effect of fat tissue volume on the distribution kinetics of biperiden as a function of age in rats.
      K Yokogawa, E Nakashima and F Ichimura
      Drug Metabolism and Disposition March 1990, 18 (2) 258-263;

  3. Yoshikawa, M

    1. Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
      M Yoshikawa, H Endo, K Komatsu, M Fujihara, O Takaiti, T Kagoshima, M Umehara and H Ishikawa
      Drug Metabolism and Disposition March 1990, 18 (2) 212-217;

Z

  1. Ziv, E

    1. The disposition of valpromide in rats and the isolated perfused rat liver.
      H Billig, E Ziv, H Bar-On and M Bialer
      Drug Metabolism and Disposition March 1990, 18 (2) 238-244;
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 18, Issue 2
1 Mar 1990
Sign up for alerts
Advertisement